The effectiveness of specialized medical dietary food product in the complex therapy of patients with pancreatitis in the acute stage

Introduction. Dietary nutrition is a physiological therapeutic and prophylactic approach for chronic pancreatitis during an exacerbation. Given the acute reaction of patients to various foods, specialized dietary products designed specifically for this pathology are of great importance.
Aim. Evaluation of the clinical efficacy, safety and tolerability of the use of specialized therapeutic nutrition – jelly “Pancreatic” in chronic pancreatitis in the acute stage.
Materials and methods. 20 patients of the main group with pancreatitis, along with standard therapy, received a dietary food product twice a day. The dynamics of pain, dyspeptic syndromes and intestinal dysfunction syndrome was studied; dynamics of the ultrasound picture of the pancreas; intestinal motility according to carbolene test; safety and tolerability of therapy by registering side effects and assessing the quality of life according to the SF-36 questionnaire, assessing well-being according to the  visual analogue scale, and the  organoleptic properties of  the medicinal product. The comparison group consisted of 20 patients who received only standard pharmacotherapy.
Results. The use of a dietary therapeutic food product is accompanied by a significant decrease in the frequency of nausea, belching, heaviness and flatulence in patients of the main group. The terms of relief or reduction in the intensity of symptoms of bitterness, nausea, heaviness in the abdomen, feelings of rapid satiety, flatulence were significantly lower in the main group (5–8 days compared to the control group (10–14 days). A significant normalization of GGT and CRP levels was established in the main group, while in the comparison group there was only a decrease in CRP. The ongoing complex therapy was accompanied by an improvement in the ultrasound picture of the pancreas, potentiation of the effects of pharmacotherapy and a significant improvement in the quality of life of patients.
Conclusions. The conducted studies have shown high efficiency, good tolerability and safety of the therapeutic product “Pancreatic jelly” in the treatment of patients with chronic pancreatitis. Kissel “Pancreas” is recommended by the authors for active use in patients with pancreatitis as a therapeutic diet.

1. Ivashkin V.T., Kriger A.G., Okhlobystin A.V., Anishchenko M.A., Kardasheva S.S., Alekseenko S.A. et al. Clinical guidelines for the diagnosis and treatment of chronic pancreatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(2):99–156. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-2-99-156.

2. Sedova G.A., Fedorov I.G., Kosyura S.D., Shustova N.S., Ilchenko L.Yu., Storozhakov G.I. Modern ideas about the classification of chronic pancreatitis. Russian Journal of Evidence-Based Gastroenterology. 2013;(1):62–67. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=18909646.

3. Imaeva A.K., Mustafin T.I., Polovinkina S.R. Morbidity and mortality rates in acute pancreatitis as an indicator of the state of medical care at the regional level. Problems of Social Hygiene, Public Health and History of Medicine. 2020;28(6):1298–1303. (In Russ.) https://doi.org/10.32687/0869-866X-2020-28-6-1298-1303.

4. Ketwaroo G.A., Freedman S.D., Sheth S.G. Approach to patients with suspected chronic pancreatitis: a comprehensive review. Pancreas. 2015;44(2):173–180. https://doi.org/10.1097/MPA.0000000000000239.

5. Machicado J.D., Amann S.T., Anderson M.A., Abberbock J., Sherman S., Conwell D. et al. 2017. Quality of life in chronic pancreatitis is determined by constant pain, disability/unemployment, current smoking and associated co-morbidities. Am J Gastroenterol. 2017;112(4):633–642. https://doi.org/10.1038/ajg.2017.

6. Yadav D., Lowenfels A.B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–1261. https://doi.org/10.1053/j.gastro.2013.01.068.

7. Maev I.V., Kucheryavy Y.A. Diseases of the pancreas. In 2 vols. Moscow: Meditsina; Shiko; 2008. Vol. 2, 558 p. (In Russ.) Available at: https://search.rsl.ru/en/record/01004165511.

8. Shimizu K., Shiratori K. Chronic pancreatitis. 1. Its epidemiology and symptoms. Nihon Naika Gakkai Zasshi. 2010;99(1):36–40. (In Japanese) https://doi.org/10.2169/naika.99.36.

9. DiMagno M.J., DiMagno E.P. chronic pancreatitis. Curr Opin Gastroenterol. 2010;26(5):490–498. https://doi.org/10.1097/MOG.0b013e32833d11b2.

10. Spanier B.W., Dijkgraaf M.G., Bruno M.J. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. Best Pract Res ClinGastroenterol. 2008;22(1):45–63. https://doi.org/10.1016/j.bpg.2007.10.007.

11. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidencebased guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl.):e1–15. https://doi.org/10.1016/j.pan.2013.07.063.

12. Forsmark C.E., Vege S.S., Wilcox C.M. Acute pancreatitis. N Engl J Med. 2016;375(20):1972–1981. https://doi.org/10.1056/NEJMra1505202.

13. Lin Y.C., Kor C.T., Su W.W., Hsu Y.C. Risk factors and prediction score for chronic pancreatitis: A nationwide population-based cohort study. World J Gastroenterol. 2018;24(44):5034–5045. https://doi.org/10.3748/wjg.v24.i44.5034.

14. Kichler A., Jang S. Chronic Pancreatitis: Epidemiology, Diagnosis, and Management Updates. Drugs. 2020;80(12):1155–1168. https://doi.org/10.1007/s40265-020-01360-6.

15. Lu M., Sun Y., Feldman R., Saul M., Althouse A., Arteel G., Yadav D. Coexistent alcohol-related cirrhosis and chronic pancreatitis have a comparable phenotype to either disease alone: A comparative retrospective analysis. World J Hepatol. 2023;15(3):431–440. https://doi.org/10.4254/wjh.v15.i3.431.

16. Singhvi A., Abromitis R., Althouse A.D., Bataller R., Arteel G.E., Yadav D. et al. Coexistence of alcohol-related pancreatitis and alcohol-related liver disease: A systematic review and meta-analysis. Pancreatology. 2020;20(6):1069–1077. https://doi.org/10.1016/j.pan.2020.07.412.

17. Di Leo M., Leandro G., Singh S.K., Mariani A., Bianco M., Zuppardo R.A. et al. Low Alcohol and Cigarette Use Is Associated to the Risk of Developing Chronic Pancreatitis. Pancreas. 2017;46:225–229. https://doi.org/10.1097/MPA.0000000000000737.

18. Lin Y.C., Kor C.T., Su W.W., Hsu Y.C. Risk factors and prediction score for chronic pancreatitis: A nationwide population-based cohort study. World J Gastroenterol. 2018;24(44):5034–5045. https://doi.org/10.3748/wjg.v24.i44.5034.

19. Vlasov A.P., Anaskin S.G., Vlasova T.I., Rubtsov O.Yu., Leshchankina N.Yu., Muratova T.A. et al. Systemic inflammatory response syndrome in pancreatic necrosis: triggers and organ damage. Pirogov Russian Journal of Surgery. 2021;(4):21–28. (In Russ.) https://doi.org/10.17116/hirurgia202104121.

20. Li G., Chen H., Liu L., Xiao P., Xie Y., Geng X. et al. Role of Interleukin-17 in Acute Pancreatitis. Front Immunol. 2021;12:674803. https://doi.org/10.3389/fimmu.2021.674803.

21. Lu M., Sun Y., Feldman R., Saul M., Althouse A., Arteel G., Yadav D. Coexistent alcohol-related cirrhosis and chronic pancreatitis have a comparable phenotype to either disease alone: A comparative retrospective analysis. World J Hepatol. 2023;15(3):431–440. https://doi.org/10.4254/wjh.v15.i3.431.

22. Pan L.L., Li J., Shamoon M., Bhatia M., Sun J. Recent advances on nutrition in treatment of acute pancreatitis. Front Immunol. 2017;8:762. https://doi.org/10.3389/fimmu.2017.00762.

23. Ardatskaya M.D., Maslovsky L.V., Zverkov I.V. Correction of disorders of the intestinal microbiota in chronic pancreatitis. Experimental and Clinical Gastroenterology. 2021;(11):52–59. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-195-11-52-59.

24. Maev I.V., Levchenko A.I., Andreev D.N. Changes in the intestinal microbiota in patients with chronic pancreatitis: systematization of literature data. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(4):17–26. (In Russ.) https://doi.org/10.22416/1382-4376-2022-32-4-17-26.

25. Tutelyan V.A., Nikityuk D.B. (eds.). Nutritiology and clinical dietology: national guidelines. 2nd ed. Moscow: GEOTAR-Media; 2021. 1002 p. (In Russ.)

26. Pilat T.L., Khanferyan R.A. Specialized dietary products as factors for improving the effectiveness of pharmacotherapy for gastrointestinal diseases. Therapy. 2020;(6):212–218. (In Russ.) https://doi.org/10.18565/therapy.2020.6.212-218